11.2 HER2-Positive Breast Cancer: Treatment Considerations
Key Takeaways
For small node-negative HER2-positive cancers, weekly paclitaxel for 12 weeks plus 1 year of trastuzumab (the APT regimen) produced about 91% invasive disease-free survival at 10 years.
HER2-positive tumors that are cT2 or larger or node-positive usually receive neoadjuvant chemotherapy with trastuzumab and pertuzumab before surgery.
After neoadjuvant therapy, a pathologic complete response leads to completing 1 year of HER2 therapy, while residual invasive disease leads to 14 cycles of ado-trastuzumab emtansine (KATHERINE).
Metastatic HER2-positive disease is treated first line with a taxane, trastuzumab, and pertuzumab (CLEOPATRA), then trastuzumab deruxtecan (DESTINY-Breast03), with tucatinib regimens favored for brain metastases.
Trastuzumab labeling advises effective contraception during treatment and for 7 months after the last dose because exposure in pregnancy can cause oligohydramnios.
Setting the Scene
HER2 is amplified or overexpressed in 15% to 20% of breast cancers. Before trastuzumab, HER2-positive disease had one of the worst prognoses; now it is among the most treatable subtypes. The drug details are in the HER2-targeted therapy section. Here the focus is on which pathway fits which patient and the nursing actions along the way.
Stage-Based Pathway
| Presentation | Typical plan |
|---|---|
| T1a N0 | Individualized; HER2 therapy may be considered |
| T1b–T1c N0 (up to 2 cm, node-negative) | Upfront surgery, then weekly paclitaxel × 12 plus trastuzumab for 1 year (APT regimen) |
| cT2 or larger, or node-positive | Neoadjuvant chemotherapy with trastuzumab and pertuzumab (for example docetaxel-carboplatin-trastuzumab-pertuzumab, or an anthracycline followed by taxane plus HP) |
| Inflammatory or locally advanced | Neoadjuvant chemotherapy plus HP, modified radical mastectomy, and radiation |
The APT trial of paclitaxel plus trastuzumab reported about 91% invasive disease-free survival at 10 years in small node-negative cancers, supporting de-escalation for these patients.
Response-Adapted Adjuvant Therapy
After neoadjuvant therapy and surgery:
- Pathologic complete response: complete 1 year of trastuzumab, with or without pertuzumab. Prognosis is excellent.
- Residual invasive disease: switch to ado-trastuzumab emtansine (T-DM1) for 14 cycles; KATHERINE showed a 50% reduction in invasive disease or death compared with trastuzumab.
- High-risk node-positive disease treated with upfront surgery: adjuvant chemotherapy with trastuzumab plus pertuzumab (APHINITY).
- Extended therapy: for HR-positive, HER2-positive disease, 1 year of neratinib after trastuzumab (ExteNET) can be considered, with mandatory diarrhea prophylaxis or dose escalation.
Trastuzumab deruxtecan-based regimens are being studied in early disease, so check current approvals before assuming a standard.
HR-Positive, HER2-Positive Disease
About half of HER2-positive cancers are also HR-positive. After chemotherapy, these patients add endocrine therapy for 5 to 10 years, given alongside ongoing HER2 therapy. Ovarian function suppression applies to high-risk premenopausal patients as in HR-positive disease.
Metastatic HER2-Positive Disease
- First line: a taxane with trastuzumab and pertuzumab (CLEOPATRA: median overall survival 56.5 versus 40.8 months).
- Second line: trastuzumab deruxtecan (DESTINY-Breast03), with vigilance for interstitial lung disease.
- Later lines and brain metastases: tucatinib plus trastuzumab and capecitabine (HER2CLIMB) improved survival, including in active brain metastases; other options include T-DM1, neratinib with capecitabine, and lapatinib combinations.
- HR-positive metastatic disease: maintenance endocrine therapy may accompany HER2 therapy after chemotherapy.
Up to 30% to 50% of patients with metastatic HER2-positive disease develop brain metastases, so neurologic symptom teaching is essential.
Nursing Safety Priorities
- Cardiac monitoring: baseline LVEF and repeat every 3 months during trastuzumab; know the hold criteria (a drop of 16% or more from baseline, or below the lower limit of normal with a drop of 10% or more). Never give trastuzumab concurrently with an anthracycline.
- Subcutaneous options: trastuzumab-hyaluronidase (600 mg every 3 weeks) and the fixed-dose pertuzumab-trastuzumab-hyaluronidase combination shorten chair time. For the combination, observe the patient for 30 minutes after the loading dose and 15 minutes after maintenance doses for hypersensitivity.
- Look-alike names: trastuzumab, ado-trastuzumab emtansine, and fam-trastuzumab deruxtecan are not interchangeable. Trastuzumab biosimilars carry four-letter suffixes. Use independent double checks, tall-man lettering, and full generic names.
- Pregnancy prevention: trastuzumab exposure during pregnancy can cause oligohydramnios and fetal harm; advise effective contraception during treatment and for 7 months after the last dose.
- Infusion reactions: most occur with the first trastuzumab dose (fever, chills); the initial infusion runs over 90 minutes, and later infusions may run over 30 minutes if tolerated.
Scheduling and Duration Details
- Total duration: HER2-directed antibody therapy is given for a total of 1 year (52 weeks), counting doses given before surgery. Every-3-week trastuzumab uses an 8 mg/kg loading dose, then 6 mg/kg.
- Missed doses: per trastuzumab labeling, if an every-3-week dose is more than 1 week late, give a new 8 mg/kg loading dose before resuming 6 mg/kg. Pertuzumab is reloaded (840 mg) if 6 weeks or more have passed since the last dose.
- Radiation and endocrine therapy: trastuzumab (and pertuzumab or T-DM1) can continue during radiation; endocrine therapy for HR-positive disease starts after chemotherapy and runs alongside HER2 therapy.
- Cardiac holds: a held dose for LVEF decline does not change the planned total duration; therapy resumes when criteria are met.
HER2 Status Can Change
HER2 expression may be heterogeneous within a tumor, and status can change after neoadjuvant therapy or at recurrence. Residual disease and first recurrences are retested. A tumor that was HER2-positive may recur as HER2-low, and vice versa, which changes options such as trastuzumab deruxtecan.
Case Walk-Through
A 44-year-old premenopausal woman has a 3-cm ER-positive, HER2-positive cancer with a positive axillary node:
- Clip the node, complete baseline echocardiogram, genetic and fertility referrals, and port placement.
- Neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab for 6 cycles, with diarrhea management, neutropenia monitoring, and LVEF every 3 months.
- Surgery shows residual invasive cancer, so she switches to T-DM1 for 14 cycles, with platelet and liver monitoring.
- Radiation to the breast and regional nodes during T-DM1.
- Endocrine therapy with ovarian function suppression because of her high risk, plus bone health monitoring and contraception counseling.
- Consideration of extended neratinib after HER2 therapy ends, weighing diarrhea risk.
A 57-year-old has a 1.4-cm, node-negative, HER2-positive, ER-negative invasive ductal carcinoma treated with lumpectomy and sentinel node biopsy. Which adjuvant regimen is best supported for this presentation?
Dose-dense doxorubicin-cyclophosphamide followed by paclitaxel with no HER2 therapy
Weekly paclitaxel for 12 weeks with trastuzumab completed to 1 year
Tamoxifen alone for 5 years
Observation, because tumors under 2 cm never need systemic therapy
After neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab, a patient's surgical pathology shows residual invasive cancer in the breast. What adjuvant HER2-directed therapy is recommended?
Ado-trastuzumab emtansine for 14 cycles
No further HER2-directed therapy
Trastuzumab alone for 5 more years
Pembrolizumab for 9 cycles
A 33-year-old receiving adjuvant trastuzumab asks how long she needs to prevent pregnancy. What should the nurse teach based on the product labeling?
Contraception is only needed until the first cycle is finished.
Pregnancy is safe once her LVEF is normal.
Use effective contraception during treatment and for 7 months after the last dose.
Hormonal contraception is preferred because it protects the heart.
Sections you finish are checked off in the contents.